Haleon (NYSE:HLN) catches the attention of the publication this week about a month after the company’s spinoff from GlaxoSmithKline (GSK). A buy recommendation is issued on the large-cap, pure-play consumer healthcare stock on the expectation for steady growth and income for investors.
Haleon is known for selling oral health products like Sensodyne and Aquafresh; over-the-counter drugs, including Advil and Theraflu, as well as vitamins and supplements like Centrum. Haleon plans a dividend payout starting in the first half of next year at the lower end of a 30% to 50% range of earning.
On the valuation front, Haleon is valued at 13.5X the consensus 2023 EPS mark, which is noted to be a lower multiple than other consumer healthcare products such as Unilever (UL) and and Procter & Gamble (PG).
Barrons also ran through all the hedge fund filings to find five stocks picked up broadly during Q2. Disney (DIS), Salesforce (CRM), Fiserv (NASDAQ:FISV), LPL Financial (NASDAQ:LPLA), and Perimeter Solutions (PRM) stood out as intriguing picks.